A phase 4 multicenter study found nearly half of patients with vitreomacular traction, with or without macular hole, who received an intravitreal injection of ocriplasmin experienced resolution by day 28.
The OVIID-1 study included 466 patients with vitreomacular traction (VMT) with focal adhesion, without epiretinal membrane and with macular hole of 400 µm or less if present. Patients received a single intravitreal injection of Jetrea (ocriplasmin, ThromboGenics), and researchers evaluated the nonsurgical resolution of VMT by day 28, best corrected visual acuity, macular hole closure,
Uncategorized